Tin tức & Cập nhật
Xem bài viết Tim mạch
Xem
New HF criteria set sizeable shift of individuals from stage A to B
The new standards for heart failure (HF) staging proposed in the 2022 American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Failure Society of America (HFSA) clinical practice guideline has led to a considerable change among community-based individuals from stage A to B.
Pioglitazone–SGLT2 inhibitor combo delivers for primary CV prevention in diabetes
Combination treatment with pioglitazone plus a sodium-glucose co-transporter 2 (SGLT2) inhibitor helps reduce the risk of developing major adverse cardiovascular events (MACE) and heart failure in individuals with type 2 diabetes mellitus (T2DM) who have no history of cardiovascular disease (CV), as reported in a study.
T2DM: SGLT2 inhibitors associated with lower rates of ICU admission and all-cause mortality
A retrospective observational study of nearly 28,000 patients with type 2 diabetes mellitus (T2DM) in Hong Kong finds that use of sodium-glucose cotransporter 2 (SGLT2) inhibitors is independently associated with lower rates of ICU admission and all-cause mortality across various disease categories.
Nitrate supplements may lower risk of diabetes complications, mortality in hyperglycaemic adults
Increased levels of urinary nitrate appear to contribute to a reduction in the risk of congestive heart failure and diabetic retinopathy and may also lower the risk of death from all causes, cardiovascular disease (CVD), and diabetes in adults with hyperglycaemia, suggests a study.
